Comments
Biocon Biologics, a subsidiary of Biocon Ltd, secured US Food and Drug Administration (FDA) approval to commercialise YESINTEK, a biosimilar.
The biosimilar drug will be used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
The company, which has entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively referred to as Janssen), plans to commercialise the drug by February 22, 2025.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.